Comparing single-dose BCD‑057 and Humira injections in healthy men

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of Single Subcutaneous Doses of BCD 057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

We will test whether single injections of two strengths of BCD‑057 act like Humira in healthy men aged 18–45.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 444 (estimated)
• Ages: 18 Years to 45 Years
• Sex: Male
• Sponsor: Biocad (Industry-sponsored)
• Drugs / interventions: adalimumab
• Locations: 4 sites (Moscow and 3 other locations)
• Trial ID: NCT07181694 on ClinicalTrials.gov

What this trial studies

Healthy male volunteers who meet screening criteria are randomized equally into three groups to receive a single subcutaneous 40 mg injection of either BCD‑057 100 mg/mL (0.4 mL), BCD‑057 50 mg/mL (0.8 mL), or Humira 100 mg/mL (0.4 mL). The main objective is to compare pharmacokinetic parameters and to monitor safety and immunogenicity after a single dose. Screening occurs up to 14 days before dosing and the main follow-up period runs from Day 1 to Day 71, with subjects stratified by body weight (<75 kg or ≥75 kg). Blood sampling and safety assessments are performed over the follow-up period to characterize PK profiles and any immune responses.

Who should consider this trial

Good fit: Healthy men 18–45 years old with BMI 18.5–30 kg/m2, normal ECG and vital signs, no chronic infections or inflammatory disease, and able to attend study visits are ideal candidates.

Not a fit: People with active autoimmune or inflammatory diseases who require therapeutic anti‑TNF treatment, women, individuals outside the age/BMI criteria, or those with chronic infections or abnormal screening tests would not benefit from participation.

Why it matters

Potential benefit: If results show comparable pharmacokinetics and safety, BCD‑057 could become an alternative biosimilar option to Humira for patients who need adalimumab.

How similar studies have performed: Previous biosimilar adalimumab programs have successfully matched Humira on pharmacokinetics and safety, so this is a well-established pathway.

Eligibility criteria

Inclusion Criteria:

1. Signing the Informed Consent Form of the study.
2. Men aged 18-45 years inclusive at the time of signing the Informed Consent Form.
3. Body mass index (BMI) in the range of 18.5-30.0 kg/m2.
4. The confirmed "healthy" status based on the conventional clinical and laboratory assessments and investigations obtained as screening.
5. Hemodynamic parameters within the normal range: systolic blood pressure (SBP) in the range of 100-130 mmHg, diastolic (DBP) in the range of 60-90 mmHg, wrist pulse rate 60-90 bpm, obtained at screening.
6. ECG data normal for the age (no ischemia, arrhythmia, conduction disorders).
7. No chronic infections (HIV, hepatitis B or C) and no history of chronic inflammatory diseases.
8. No signs of active or latent tuberculosis according to screening X-ray and tuberculosis test results.
9. No acute infections within 4 weeks prior to the date of randomization.
10. The ability of the subject to follow the Protocol procedures, according to the Investigator.
11. No history of alcoholism or drug addiction and negative test results for alcohol, psychotropic and narcotic substances, psychoactive drugs at screening and before the IP administration.
12. Willingness of subjects to use condoms during any sexual contact by penetration with persons of any sex, including pregnant women, starting from the signing of the Informed Consent Form, during the study and for 5 months after the IP administration. This requirement does not apply to subjects who have undergone surgical sterilization (bilateral orchiectomy).
13. Willingness to refuse to donate sperm and conceive a child starting from the signing of the Informed Consent Form, during the study and for 5 months after the IP administration.
14. Willingness not to drink alcohol within 24 hours before and after the IP administration, within 24 hours before each scheduled visit.
15. Willingness to refrain from smoking within 2 hours before the IP administration and then 2 hours before each measurement of blood pressure (BP), wrist pulse rate, respiratory rate, blood sampling, ECG.
16. Willingness to refrain from vaccination with live attenuated vaccines (e.g., intranasal influenza, measles, mumps, rubella, polio, BCG, yellow fever, chickenpox, and typhoid TY21a vaccines) throughout the study.
17. Willingness to refrain from taking any medications, including over-the-counter drugs, vitamins and food supplements, with the exception of drugs prescribed by the Investigator for the treatment of AEs, throughout the study.

Exclusion Criteria:

1. Mental illness or other conditions that may, in the Investigator's opinion, affect the subject's ability to comply with the Study Protocol.
2. Any significant, in the Investigator's opinion, surgical procedures performed less than 30 days before the screening examination and potentially affecting clinical study results.
3. A history of allergic reactions (anaphylactic shock or multiple drug allergy according to the Investigator's assessment).
4. Known allergy or intolerance to monoclonal antibody products (murine, chimeric, humanized, fully human) or any other components of the IP.
5. Impossibility of installing a venous catheter for collecting blood samples (e.g., due to skin disorders at the venipuncture sites).
6. Administration and use of the following drugs:

   1. Past use of adalimumab or any other drugs that inhibit tumor necrosis factor alpha.
   2. Regular oral or parenteral administration of any medicinal products, including over-the-counter drugs, vitamins, and dietary supplements, less than 14 days prior to the estimated date of randomization.
   3. Taking medications, including over-the-counter drugs, which have a pronounced effect on hemodynamics and liver function (barbiturates, omeprazole, cimetidine, etc.), less than 30 days before the estimated date of randomization.
   4. Using drugs that affect the immune status (cytokines and their inducers, glucocorticoids, etc.) less than 30 days before the estimated date of randomization.
   5. Systemic use of antibacterial, antifungal, antiviral or antiprotozoal drugs less than 30 days before the estimated date of randomization.
   6. Vaccination with live attenuated vaccines within 4 weeks before the estimated date of randomization.
7. Positive results of screening tests for HIV, hepatitis B and C viruses.
8. Results of conventional laboratory tests or investigations out of the reference ranges accepted at the study sites.
9. Chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, kidneys, blood.
10. Acute infectious diseases less than 4 weeks before the estimated date of randomization, as well as chronic and other diseases that, in the Investigator's opinion, may affect the pharmacokinetics, safety, and immunogenicity of the IP.
11. Smoking more than 10 cigarettes a day.
12. Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to ½ L of beer, 200 mL of wine or 50 mL of spirits) or a history of alcoholism, drug addiction, or drug abuse.of blood or plasma within 60 calendar days prior to the expected date of randomization.
13. Donation of ≥450 mL of blood or plasma within 60 calendar days prior to the expected date of randomization.
14. Participation in any clinical studies in less than 90 calendar days before the date of randomization, if the subject received a medicinal product during the clinical study.
15. Previous participation in the same study if the subject was randomized and received the IP during the study.

Where this trial is running

Moscow and 3 other locations

• I.M. Sechenov First Moscow State Medical University — Moscow, Russia (Recruiting)
• LLC "X7 Clinical Research" — Saint Petersburg, Russia (Recruiting)
• LLC "Research Center Eco-Safety" — Saint Petersburg, Russia (Recruiting)
• LLC "X7 Clinical Research" — Saint Petersburg, Russia (Recruiting)

Study contacts

• Study coordinator: Svyatoslav I Klimshin

Conditions Healthy Adult Male; Tumor Necrosis Factor Inhibitors; Anti-Inflammatory Agents; Adalimumab; Monoclonal Antibody; Pharmacokinetics